🔎 Trials Near Me

Utama › Kanser Pankreas › Nebraska

Kajian klinikal Kanser Pankreas di Nebraska

14 kajian untuk Kanser Pankreas sedang mencari peserta di lokasi di Nebraska.

Bandar di Nebraska

Teks kajian rasmi (Bahasa Inggeris)

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277413

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  • Nebraska Medicine, Omaha
  • Nebraska Medicine - Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06989437

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07252232

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

  • Nebraska Cancer Specialists, Omaha
  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06445062

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

  • University of Nebraska Medical Center, Omaha
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06271291

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT06958328

Pancreatic Cancer Early Detection Consortium

  • University of Nebraska Medical Center, Omaha
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 90 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT04970056

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

  • NHO Revive Research Institute, Lincoln
  • Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT06937177

Integrated Cancer Repository for Cancer Research

  • Mary Lanning Healthcare, Morrison Cancer Center, Hastings
  • Faith Regional Health Services, Carson Cancer Center, Norfolk
  • Great Plains Regional Medical Center, North Platte
  • dan 3 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

  • CHI Health Saint Francis, Grand Island
  • CHI Health Good Samaritan, Kearney
  • Alegent Health Immanuel Medical Center, Omaha
  • dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Mei 2026 · NCT06998940

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  • Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Feb 2026 · NCT07030257

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

  • Ohio State University Telemedicine, North Platte
  • Ohio State University-Telemedicine, Omaha
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Feb 2026 · NCT06906562

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.